{"id":6707,"date":"2026-03-20T15:14:53","date_gmt":"2026-03-20T08:14:53","guid":{"rendered":"https:\/\/wincolaw.com.vn\/?p=6707"},"modified":"2026-03-20T15:18:50","modified_gmt":"2026-03-20T08:18:50","slug":"tranh-chap-duoc-pham","status":"publish","type":"post","link":"https:\/\/wincolaw.com.vn\/vi\/tranh-chap-duoc-pham.html","title":{"rendered":"Tranh ch\u1ea5p d\u01b0\u1ee3c ph\u1ea9m"},"content":{"rendered":"

T\u00f2a \u00e1n T\u1ed1i cao \u00dac \u0111\u00e3 cho ph\u00e9p c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m Otsuka kh\u00e1ng c\u00e1o trong m\u1ed9t v\u1ee5 tranh ch\u1ea5p v\u1ec1 gia h\u1ea1n th\u1eddi h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf (Patent Term Extension-PTE).<\/p>\n

Ng\u00e0y 12\/3\/2026, High Court of Australia (T\u00f2a \u00e1n T\u1ed1i cao \u00dac) \u0111\u00e3 cho ph\u00e9p (grant special leave) c\u00f4ng ty Otsuka Pharmaceutical Co., Ltd. kh\u00e1ng c\u00e1o quy\u1ebft \u0111\u1ecbnh c\u1ee7a t\u00f2a c\u1ea5p d\u01b0\u1edbi trong v\u1ee5 ki\u1ec7n v\u1edbi Sun Pharma ANZ Pty Ltd. \u0110i\u1ec1u n\u00e0y c\u00f3 ngh\u0129a l\u00e0 T\u00f2a t\u1ed1i cao s\u1ebd xem x\u00e9t l\u1ea1i ph\u00e1n quy\u1ebft tr\u01b0\u1edbc \u0111\u00f3 c\u1ee7a t\u00f2a ph\u00fac th\u1ea9m li\u00ean bang \u00dac.<\/p>\n

H\u00e3y c\u00f9ng \u0111i s\u00e2u v\u00e0o t\u1ea7m quan tr\u1ecdng c\u1ee7a “formulation patents” (b\u1eb1ng s\u00e1ng ch\u1ebf c\u00f4ng th\u1ee9c thu\u1ed1c) v\u00e0 l\u00fd do t\u1ea1i sao c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m lu\u00f4n r\u1ea5t ch\u00fa tr\u1ecdng v\u00e0o ch\u00fang, \u0111\u1eb7c bi\u1ec7t trong vi\u1ec7c gia h\u1ea1n Patent Term Extension (PTE).<\/p>\n

1\/ Formulation Patent l\u00e0 g\u00ec?<\/strong><\/p>\n

Formulation patents l\u00e0 nh\u1eefng b\u1eb1ng s\u00e1ng ch\u1ebf b\u1ea3o v\u1ec7 c\u00f4ng th\u1ee9c b\u00e0o ch\u1ebf c\u1ee7a m\u1ed9t lo\u1ea1i thu\u1ed1c. \u0110i\u1ec1u n\u00e0y kh\u00f4ng ch\u1ec9 bao g\u1ed3m th\u00e0nh ph\u1ea7n ch\u00ednh (active ingredient), m\u00e0 c\u00f2n m\u00f4 t\u1ea3 c\u00e1ch k\u1ebft h\u1ee3p, pha ch\u1ebf v\u00e0 s\u1ea3n xu\u1ea5t thu\u1ed1c sao cho n\u00f3 c\u00f3 th\u1ec3 ph\u00e1t huy hi\u1ec7u qu\u1ea3 t\u1ed1t nh\u1ea5t, bao g\u1ed3m c\u1ea3 d\u1ea1ng thu\u1ed1c (v\u00ed d\u1ee5: vi\u00ean n\u00e9n, thu\u1ed1c l\u1ecfng, thu\u1ed1c ph\u00f3ng th\u00edch ch\u1eadm, ti\u00eam).<\/p>\n

V\u00ed d\u1ee5: C\u00f4ng th\u1ee9c thu\u1ed1c c\u1ee7a m\u1ed9t lo\u1ea1i thu\u1ed1c ph\u00f3ng th\u00edch ch\u1eadm (extended-release formulation) s\u1ebd kh\u00e1c v\u1edbi thu\u1ed1c th\u00f4ng th\u01b0\u1eddng v\u00ec n\u00f3 c\u00f3 th\u00eam th\u00e0nh ph\u1ea7n gi\u00fap thu\u1ed1c gi\u1ea3i ph\u00f3ng d\u1ea7n d\u1ea7n qua th\u1eddi gian.<\/p>\n

2\/ S\u1ef1 kh\u00e1c bi\u1ec7t gi\u1eefa “formulation patents” v\u00e0 “API patents”<\/strong><\/p>\n

Active Pharmaceutical Ingredient (API): \u0110\u00e2y l\u00e0 th\u00e0nh ph\u1ea7n ch\u00ednh c\u1ee7a thu\u1ed1c, v\u00ed d\u1ee5 nh\u01b0 m\u1ed9t lo\u1ea1i h\u00f3a ch\u1ea5t ch\u1eefa b\u1ec7nh (aripiprazole, aspirin, v.v.).<\/p>\n

Formulation: Bao g\u1ed3m c\u00e1c th\u00e0nh ph\u1ea7n ph\u1ee5 kh\u00e1c \u0111\u1ec3 gi\u00fap thu\u1ed1c ho\u1ea1t \u0111\u1ed9ng \u0111\u00fang c\u00e1ch (v\u00ed d\u1ee5: dung m\u00f4i, ch\u1ea5t k\u1ebft d\u00ednh, ch\u1ea5t b\u1ea3o qu\u1ea3n) v\u00e0 d\u1ea1ng b\u00e0o ch\u1ebf (ph\u00f3ng th\u00edch ch\u1eadm, tan trong d\u1ea1 d\u00e0y, v.v.).<\/p>\n

3\/ T\u1ea1i sao “Formulation Patents” l\u1ea1i quan tr\u1ecdng \u0111\u1ed1i v\u1edbi c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m?<\/strong><\/p>\n

B\u1eb1ng s\u00e1ng ch\u1ebf c\u00f4ng th\u1ee9c thu\u1ed1c r\u1ea5t quan tr\u1ecdng v\u00ec ch\u00fang c\u00f3 th\u1ec3 m\u1edf r\u1ed9ng \u0111\u1ed9c quy\u1ec1n c\u1ee7a s\u1ea3n ph\u1ea9m v\u00e0 \u0111em l\u1ea1i l\u1ee3i th\u1ebf th\u01b0\u01a1ng m\u1ea1i l\u1edbn cho c\u00e1c c\u00f4ng ty. D\u01b0\u1edbi \u0111\u00e2y l\u00e0 m\u1ed9t s\u1ed1 l\u00fd do quan tr\u1ecdng:<\/p>\n

    \n
  1. M\u1edf r\u1ed9ng th\u1eddi gian b\u1ea3o v\u1ec7 \u0111\u1ed9c quy\u1ec1n
    \nB\u1eb1ng s\u00e1ng ch\u1ebf cho API ch\u1ec9 b\u1ea3o v\u1ec7 th\u00e0nh ph\u1ea7n ho\u1ea1t ch\u1ea5t c\u1ee7a thu\u1ed1c, c\u00f3 th\u1eddi gian b\u1ea3o v\u1ec7 20 n\u0103m. Tuy nhi\u00ean, c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m c\u00f3 th\u1ec3 c\u1ea3i ti\u1ebfn c\u00f4ng th\u1ee9c thu\u1ed1c \u0111\u1ec3 t\u1ea1o ra c\u00e1c d\u1ea1ng thu\u1ed1c m\u1edbi (v\u00ed d\u1ee5: ph\u00f3ng th\u00edch ch\u1eadm, \u0111i\u1ec1u ch\u1ec9nh d\u1ea1ng b\u00e0o ch\u1ebf). N\u1ebfu c\u00f4ng th\u1ee9c thu\u1ed1c (formulation) \u0111\u01b0\u1ee3c c\u1ea5p b\u1eb1ng s\u00e1ng ch\u1ebf ri\u00eang bi\u1ec7t, c\u00f4ng ty c\u00f3 th\u1ec3 gia h\u1ea1n quy\u1ec1n \u0111\u1ed9c quy\u1ec1n th\u00eam v\u00e0i n\u0103m, gi\u00fap \u0111\u1ea9y l\u00f9i s\u1ef1 c\u1ea1nh tranh t\u1eeb c\u00e1c s\u1ea3n ph\u1ea9m generic (thu\u1ed1c b\u1ea3n sao). PTE cho ph\u00e9p c\u00f4ng ty gia h\u1ea1n th\u00eam th\u1eddi gian \u0111\u1ed9c quy\u1ec1n sau khi b\u1eb1ng s\u00e1ng ch\u1ebf cho API \u0111\u00e3 h\u1ebft hi\u1ec7u l\u1ef1c, gi\u00fap h\u1ecd duy tr\u00ec l\u1ee3i nhu\u1eadn t\u1eeb thu\u1ed1c trong th\u1eddi gian d\u00e0i h\u01a1n.<\/li>\n
  2. C\u1ea3i ti\u1ebfn v\u00e0 \u0111\u1ed5i m\u1edbi trong \u0111i\u1ec1u tr\u1ecb
    \nVi\u1ec7c ph\u00e1t tri\u1ec3n nh\u1eefng d\u1ea1ng thu\u1ed1c m\u1edbi (v\u00ed d\u1ee5: thu\u1ed1c ph\u00f3ng th\u00edch ch\u1eadm, thu\u1ed1c ti\u00eam thay v\u00ec u\u1ed1ng) c\u00f3 th\u1ec3 gi\u00fap c\u1ea3i thi\u1ec7n hi\u1ec7u qu\u1ea3 \u0111i\u1ec1u tr\u1ecb, gi\u1ea3m t\u00e1c d\u1ee5ng ph\u1ee5, v\u00e0 t\u1ed1i \u01b0u h\u00f3a vi\u1ec7c s\u1eed d\u1ee5ng thu\u1ed1c cho b\u1ec7nh nh\u00e2n.C\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m c\u00f3 th\u1ec3 s\u1eed d\u1ee5ng formulation patents \u0111\u1ec3 b\u1ea3o v\u1ec7 c\u00e1c s\u00e1ng ch\u1ebf n\u00e0y v\u00e0 ng\u0103n ch\u1eb7n c\u00e1c c\u00f4ng ty kh\u00e1c sao ch\u00e9p c\u00f4ng th\u1ee9c c\u1ee7a h\u1ecd.<\/li>\n
  3. Ng\u0103n ch\u1eb7n s\u1ef1 x\u00e2m nh\u1eadp c\u1ee7a thu\u1ed1c generic
    \nM\u1ed9t khi b\u1eb1ng s\u00e1ng ch\u1ebf API h\u1ebft h\u1ea1n, c\u00e1c c\u00f4ng ty generic (s\u1ea3n xu\u1ea5t thu\u1ed1c b\u1ea3n sao) c\u00f3 th\u1ec3 b\u1eaft \u0111\u1ea7u s\u1ea3n xu\u1ea5t v\u00e0 b\u00e1n thu\u1ed1c v\u1edbi gi\u00e1 th\u1ea5p h\u01a1n.Tuy nhi\u00ean, n\u1ebfu c\u00f4ng ty s\u1edf h\u1eefu formulation patent cho m\u1ed9t d\u1ea1ng thu\u1ed1c m\u1edbi (v\u00ed d\u1ee5: ph\u00f3ng th\u00edch ch\u1eadm), h\u1ecd v\u1eabn c\u00f3 th\u1ec3 ng\u0103n c\u1ea3n ho\u1eb7c tr\u00ec ho\u00e3n s\u1ef1 ra \u0111\u1eddi c\u1ee7a c\u00e1c s\u1ea3n ph\u1ea9m generic.Formulation patent l\u00e0 m\u1ed9t c\u00f4ng c\u1ee5 quan tr\u1ecdng \u0111\u1ec3 duy tr\u00ec \u0111\u1ed9c quy\u1ec1n th\u1ecb tr\u01b0\u1eddng, ngay c\u1ea3 khi b\u1eb1ng s\u00e1ng ch\u1ebf cho API \u0111\u00e3 h\u1ebft h\u1ea1n.<\/li>\n
  4. L\u1ee3i th\u1ebf c\u1ea1nh tranh trong vi\u1ec7c ti\u1ebfp c\u1eadn th\u1ecb tr\u01b0\u1eddng
    \nC\u00e1c c\u00f4ng ty s\u1edf h\u1eefu formulation patent c\u00f3 th\u1ec3 cung c\u1ea5p thu\u1ed1c v\u1edbi \u0111\u1eb7c t\u00ednh v\u01b0\u1ee3t tr\u1ed9i h\u01a1n (v\u00ed d\u1ee5: gi\u1ea3m thi\u1ec3u t\u00e1c d\u1ee5ng ph\u1ee5, c\u1ea3i thi\u1ec7n s\u1ef1 h\u1ea5p th\u1ee5) v\u00e0 c\u00f3 th\u1ec3 \u0111\u1ecbnh gi\u00e1 cao h\u01a1n v\u00ec n\u00f3 c\u00f3 s\u1ef1 kh\u00e1c bi\u1ec7t r\u00f5 r\u00e0ng so v\u1edbi s\u1ea3n ph\u1ea9m ban \u0111\u1ea7u.\u0110i\u1ec1u n\u00e0y gi\u00fap c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m duy tr\u00ec v\u1ecb th\u1ebf c\u1ea1nh tranh v\u00e0 t\u0103ng tr\u01b0\u1edfng doanh thu.<\/li>\n<\/ol>\n

    4\/ \u1ea2nh h\u01b0\u1edfng c\u1ee7a quy\u1ebft \u0111\u1ecbnh c\u1ee7a T\u00f2a \u00e1n T\u1ed1i cao \u00dac trong v\u1ee5 Otsuka<\/strong><\/p>\n

    N\u1ebfu T\u00f2a \u00e1n T\u1ed1i cao \u00dac x\u00e1c nh\u1eadn quy\u1ebft \u0111\u1ecbnh tr\u01b0\u1edbc \u0111\u00f3 c\u1ee7a t\u00f2a ph\u00fac th\u1ea9m, c\u00e1c c\u00f4ng ty s\u1ebd kh\u00f4ng c\u00f2n c\u00f3 th\u1ec3 gia h\u1ea1n th\u00eam th\u1eddi gian b\u1ea3o v\u1ec7 cho c\u00e1c b\u1eb1ng s\u00e1ng ch\u1ebf formulation patents n\u1eefa.<\/p>\n

    \u0110i\u1ec1u n\u00e0y c\u00f3 th\u1ec3 t\u1ea1o ra m\u1ed9t l\u1ed7 h\u1ed5ng trong h\u1ec7 th\u1ed1ng b\u1ea3o v\u1ec7 quy\u1ec1n l\u1ee3i d\u01b0\u1ee3c ph\u1ea9m, khi\u1ebfn nhi\u1ec1u c\u00f4ng ty ph\u1ea3i t\u00ecm c\u00e1ch kh\u00e1c \u0111\u1ec3 b\u1ea3o v\u1ec7 s\u00e1ng ch\u1ebf c\u1ee7a m\u00ecnh.<\/p>\n

    Ng\u01b0\u1ee3c l\u1ea1i, n\u1ebfu T\u00f2a \u00e1n cho ph\u00e9p gia h\u1ea1n, \u0111i\u1ec1u n\u00e0y s\u1ebd c\u1ee7ng c\u1ed1 gi\u00e1 tr\u1ecb c\u1ee7a formulation patents \u00a0v\u00e0 c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m s\u1ebd ti\u1ebfp t\u1ee5c c\u00f3 \u0111\u1ed9ng l\u1ef1c ph\u00e1t tri\u1ec3n c\u00e1c s\u1ea3n ph\u1ea9m c\u1ea3i ti\u1ebfn, m\u1edf r\u1ed9ng ph\u1ea1m vi b\u1ea3o v\u1ec7 s\u00e1ng ch\u1ebf.<\/p>\n

    \u00a0T\u00f3m l\u1ea1i<\/strong><\/p>\n

    Formulation patents l\u00e0 m\u1ed9t ph\u1ea7n kh\u00f4ng th\u1ec3 thi\u1ebfu trong chi\u1ebfn l\u01b0\u1ee3c b\u1ea3o v\u1ec7 quy\u1ec1n l\u1ee3i c\u1ee7a c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m, b\u1edfi v\u00ec ch\u00fang gi\u00fap duy tr\u00ec quy\u1ec1n \u0111\u1ed9c quy\u1ec1n, t\u0103ng tr\u01b0\u1edfng doanh thu, v\u00e0 ng\u0103n ch\u1eb7n s\u1ef1 x\u00e2m nh\u1eadp c\u1ee7a thu\u1ed1c generic. Quy\u1ebft \u0111\u1ecbnh c\u1ee7a T\u00f2a \u00e1n T\u1ed1i cao \u00dac trong v\u1ee5 Otsuka c\u00f3 th\u1ec3 s\u1ebd c\u00f3 \u1ea3nh h\u01b0\u1edfng l\u1edbn \u0111\u1ebfn c\u00e1ch c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m b\u1ea3o v\u1ec7 s\u00e1ng ch\u1ebf c\u1ee7a m\u00ecnh v\u00e0 chi\u1ebfn l\u01b0\u1ee3c ph\u00e1t tri\u1ec3n s\u1ea3n ph\u1ea9m trong t\u01b0\u01a1ng lai.<\/p>\n

    5\/ Tranh ch\u1ea5p ph\u00e1p l\u00fd l\u00e0 g\u00ec?<\/strong><\/p>\n

    V\u1ee5 ki\u1ec7n xoay quanh gia h\u1ea1n th\u1eddi h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf (Patent Term Extension \u2013 PTE) cho thu\u1ed1c c\u1ee7a Otsuka.<\/p>\n

    PTE l\u00e0 g\u00ec?<\/p>\n

    B\u1eb1ng s\u00e1ng ch\u1ebf d\u01b0\u1ee3c ph\u1ea9m th\u01b0\u1eddng c\u00f3 th\u1eddi h\u1ea1n 20 n\u0103m.<\/p>\n

    \u1ede \u00dac, c\u00f3 th\u1ec3 gia h\u1ea1n th\u00eam t\u1ed1i \u0111a 5 n\u0103m \u0111\u1ec3 b\u00f9 cho th\u1eddi gian th\u1eed nghi\u1ec7m v\u00e0 xin c\u1ea5p ph\u00e9p thu\u1ed1c.<\/p>\n

    6\/ Ph\u00e1n quy\u1ebft tr\u01b0\u1edbc \u0111\u00f3 c\u1ee7a t\u00f2a ph\u00fac th\u1ea9m<\/strong><\/p>\n

    Trong v\u1ee5 Otsuka v Sun Pharma (2025), Full Federal Court \u0111\u00e3 ph\u00e1n quy\u1ebft r\u1eb1ng:<\/p>\n

    Ch\u1ec9 b\u1eb1ng s\u00e1ng ch\u1ebf cho \u201cho\u1ea1t ch\u1ea5t d\u01b0\u1ee3c ph\u1ea9m\u201d (active pharmaceutical ingredient \u2013 API) m\u1edbi \u0111\u1ee7 \u0111i\u1ec1u ki\u1ec7n \u0111\u01b0\u1ee3c gia h\u1ea1n PTE.<\/p>\n

    B\u1eb1ng s\u00e1ng ch\u1ebf v\u1ec1 \u201cc\u00f4ng th\u1ee9c b\u00e0o ch\u1ebf\u201d (formulation) c\u1ee7a thu\u1ed1c kh\u00f4ng \u0111\u01b0\u1ee3c gia h\u1ea1n.<\/p>\n

    \u0110i\u1ec1u n\u00e0y khi\u1ebfn b\u1eb1ng s\u00e1ng ch\u1ebf c\u1ee7a Otsuka cho d\u1ea1ng b\u00e0o ch\u1ebf ph\u00f3ng th\u00edch ch\u1eadm c\u1ee7a aripiprazole kh\u00f4ng \u0111\u01b0\u1ee3c gia h\u1ea1n.<\/p>\n

    V\u00ec sao v\u1ee5 n\u00e0y quan tr\u1ecdng?<\/p>\n

    N\u1ebfu ph\u00e1n quy\u1ebft c\u1ee7a t\u00f2a ph\u00fac th\u1ea9m \u0111\u01b0\u1ee3c gi\u1eef nguy\u00ean: R\u1ea5t nhi\u1ec1u b\u1eb1ng s\u00e1ng ch\u1ebf thu\u1ed1c d\u1ea1ng formulation \u1edf \u00dac s\u1ebd kh\u00f4ng c\u00f2n \u0111\u01b0\u1ee3c gia h\u1ea1n.Nhi\u1ec1u PTE \u0111\u00e3 c\u1ea5p tr\u01b0\u1edbc \u0111\u00e2y c\u00f3 th\u1ec3 b\u1ecb th\u00e1ch th\u1ee9c ho\u1eb7c b\u1ecb v\u00f4 hi\u1ec7u. \u0110i\u1ec1u n\u00e0y c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng l\u1edbn \u0111\u1ebfn chi\u1ebfn l\u01b0\u1ee3c b\u1ea3o h\u1ed9 s\u00e1ng ch\u1ebf c\u1ee7a c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c tr\u00ean to\u00e0n c\u1ea7u.<\/p>\n

    B\u01b0\u1edbc ti\u1ebfp theo sau khi cho ph\u00e9p kh\u00e1ng c\u00e1o:T\u00f2a T\u1ed1i cao \u00dac s\u1ebd x\u00e9t x\u1eed v\u00e0 quy\u1ebft \u0111\u1ecbnh cu\u1ed1i c\u00f9ng v\u1ec1 vi\u1ec7c li\u1ec7u b\u1eb1ng s\u00e1ng ch\u1ebf formulation c\u1ee7a thu\u1ed1c c\u00f3 \u0111\u01b0\u1ee3c gia h\u1ea1n PTE hay kh\u00f4ng. Quy\u1ebft \u0111\u1ecbnh n\u00e0y c\u00f3 th\u1ec3 t\u00e1i \u0111\u1ecbnh h\u00ecnh lu\u1eadt b\u1eb1ng s\u00e1ng ch\u1ebf d\u01b0\u1ee3c ph\u1ea9m t\u1ea1i \u00dac.<\/p>\n

    Tham kh\u1ea3o t\u1eeb c\u00e1c ngu\u1ed3n: <\/em><\/p>\n

    https:\/\/www.pearceip.law\/2026\/03\/12\/breaking-news-australian-high-court-grants-leave-to-appeal-to-otsuka-in-pte-dispute\/<\/a><\/p>\n

    https:\/\/www.spruson.com\/australias-high-court-to-decide-the-future-of-patent-term-extensions-for-pharmaceutical-formulation-patents<\/a><\/p>\n

    https:\/\/www.fbrice.com.au\/ip-news-insights\/patent-term-extension-saga-continues-australian-high-court-prescribes-a-hearing-for-formulation-claims<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    T\u00f2a \u00e1n T\u1ed1i cao \u00dac \u0111\u00e3 cho ph\u00e9p c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m Otsuka kh\u00e1ng c\u00e1o trong m\u1ed9t v\u1ee5 tranh ch\u1ea5p v\u1ec1 gia h\u1ea1n th\u1eddi h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf (Patent Term Extension-PTE). Ng\u00e0y 12\/3\/2026, High Court of Australia (T\u00f2a \u00e1n T\u1ed1i cao \u00dac) \u0111\u00e3 cho ph\u00e9p (grant special leave) c\u00f4ng ty Otsuka Pharmaceutical Co., Ltd. kh\u00e1ng […]<\/p>\n","protected":false},"author":1,"featured_media":5419,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[101,9],"tags":[],"yst_prominent_words":[],"class_list":["post-6707","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-so-huu-tri-tue","category-tin-tuc"],"_links":{"self":[{"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/posts\/6707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/comments?post=6707"}],"version-history":[{"count":3,"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/posts\/6707\/revisions"}],"predecessor-version":[{"id":6710,"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/posts\/6707\/revisions\/6710"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/media\/5419"}],"wp:attachment":[{"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/media?parent=6707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/categories?post=6707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/tags?post=6707"},{"taxonomy":"yst_prominent_words","embeddable":true,"href":"https:\/\/wincolaw.com.vn\/vi\/wp-json\/wp\/v2\/yst_prominent_words?post=6707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}